Pacira BioSciences Statistics
Share Statistics
Pacira BioSciences has 46.17M shares outstanding. The number of shares has increased by -0.7% in one year.
| Shares Outstanding | 46.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 44.70M |
| Failed to Deliver (FTD) Shares | 253 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 4.75M, so 10.29% of the outstanding shares have been sold short.
| Short Interest | 4.75M |
| Short % of Shares Out | 10.29% |
| Short % of Float | 10.66% |
| Short Ratio (days to cover) | 6.18 |
Valuation Ratios
The PE ratio is 37.17 and the forward PE ratio is 5.54. Pacira BioSciences 's PEG ratio is 0.1.
| PE Ratio | 37.17 |
| Forward PE | 5.54 |
| PS Ratio | 2.31 |
| Forward PS | 1.3 |
| PB Ratio | 1.79 |
| P/FCF Ratio | 11.18 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Pacira BioSciences Inc. has an Enterprise Value (EV) of 1.99B.
| EV / Earnings | 47.49 |
| EV / Sales | 2.95 |
| EV / EBITDA | 12.64 |
| EV / EBIT | 22.72 |
| EV / FCF | 14.28 |
Financial Position
The company has a current ratio of 5.24, with a Debt / Equity ratio of 0.67.
| Current Ratio | 5.24 |
| Quick Ratio | 4.17 |
| Debt / Equity | 0.67 |
| Total Debt / Capitalization | 40.25 |
| Cash Flow / Debt | 0.26 |
| Interest Coverage | 4.32 |
Financial Efficiency
Return on equity (ROE) is 0.05% and return on capital (ROIC) is 4.09%.
| Return on Equity (ROE) | 0.05% |
| Return on Assets (ROA) | 0.03% |
| Return on Capital (ROIC) | 4.09% |
| Revenue Per Employee | 949.34K |
| Profits Per Employee | 59.01K |
| Employee Count | 711 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | 19.75M |
| Effective Tax Rate | 0.32 |
Stock Price Statistics
The stock price has increased by -36.44% in the last 52 weeks. The beta is 0.82, so Pacira BioSciences 's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -36.44% |
| 50-Day Moving Average | 18.3 |
| 200-Day Moving Average | 20.98 |
| Relative Strength Index (RSI) | 61.86 |
| Average Volume (20 Days) | 698.11K |
Income Statement
In the last 12 months, Pacira BioSciences had revenue of 674.98M and earned 41.95M in profits. Earnings per share was 0.91.
| Revenue | 674.98M |
| Gross Profit | 490.31M |
| Operating Income | 87.67M |
| Net Income | 41.95M |
| EBITDA | 157.58M |
| EBIT | 87.67M |
| Earnings Per Share (EPS) | 0.91 |
Balance Sheet
The company has 153.30M in cash and 586.04M in debt, giving a net cash position of -432.75M.
| Cash & Cash Equivalents | 153.30M |
| Total Debt | 586.04M |
| Net Cash | -432.75M |
| Retained Earnings | -106.80M |
| Total Assets | 1.52B |
| Working Capital | 383.57M |
Cash Flow
In the last 12 months, operating cash flow was 154.65M and capital expenditures -15.16M, giving a free cash flow of 139.49M.
| Operating Cash Flow | 154.65M |
| Capital Expenditures | -15.16M |
| Free Cash Flow | 139.49M |
| FCF Per Share | 3.02 |
Margins
Gross margin is 72.64%, with operating and profit margins of 12.99% and 6.22%.
| Gross Margin | 72.64% |
| Operating Margin | 12.99% |
| Pretax Margin | 9.14% |
| Profit Margin | 6.22% |
| EBITDA Margin | 23.35% |
| EBIT Margin | 12.99% |
| FCF Margin | 20.67% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 4.43% |
| FCF Yield | 14.7% |
Analyst Forecast
The average price target for PCRX is $24, which is 16.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 16.8% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 1.1 |
| Piotroski F-Score | 6 |